- Home
- CLIR vs OTLK Comparison
CLIR vs OTLK Comparison
Compare CLIR & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLIR | OTLK |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.4M | 38.7M |
| IPO Year | 2012 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CLIR | OTLK |
|---|---|---|
| Price | $0.72 | $0.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.00 | ★ $3.83 |
| AVG Volume (30 Days) | 147.0K | ★ 13.1M |
| Earning Date | 11-14-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,153,000.00 | $1,413,535.00 |
| Revenue This Year | $13.13 | $1,578.49 |
| Revenue Next Year | $143.88 | $153.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.46 | $0.50 |
| 52 Week High | $1.53 | $3.39 |
Technical Indicators
Market Signals| Indicator | CLIR | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 26.06 |
| Support Level | $0.63 | $0.51 |
| Resistance Level | $0.81 | $0.56 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 59.00 | 14.45 |
Price Performance
Historical ComparisonAbout CLIR ClearSign Technologies Corporation (DE)
ClearSign Technologies Corp is engaged in providing solutions to some of the pressing productivity, energy efficiency, and pollution problems affecting the energy, oil, and gas production, boiler, and processing industries. It believes that its patented ClearSign Core technology can enhance the performance of combustion systems in a broad range of markets, including the energy (upstream oil production and downstream refining), institutional, commercial, and industrial boiler, chemical, and petrochemical industries. The company offers products that include process burners, boiler burners, flares, and ClearSign Eye.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.